Revium Rx. Statistics
Total Valuation
Revium Rx. has a market cap or net worth of 86.84 million. The enterprise value is 85.47 million.
| Market Cap | 86.84M |
| Enterprise Value | 85.47M |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Revium Rx. has 60.73 million shares outstanding. The number of shares has increased by 8.59% in one year.
| Current Share Class | 60.73M |
| Shares Outstanding | 60.73M |
| Shares Change (YoY) | +8.59% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 63.91% |
| Owned by Institutions (%) | n/a |
| Float | 21.92M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 15.74 |
| P/TBV Ratio | 194.28 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.91, with a Debt / Equity ratio of 0.02.
| Current Ratio | 1.91 |
| Quick Ratio | 1.55 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.05 |
| Interest Coverage | -1,630.00 |
Financial Efficiency
Return on equity (ROE) is -109.89% and return on invested capital (ROIC) is -16.81%.
| Return on Equity (ROE) | -109.89% |
| Return on Assets (ROA) | -15.47% |
| Return on Invested Capital (ROIC) | -16.81% |
| Return on Capital Employed (ROCE) | -53.11% |
| Weighted Average Cost of Capital (WACC) | -0.08% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -2.65M |
| Employee Count | 6 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Revium Rx. has paid 358,000 in taxes.
| Income Tax | 358,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +175.00% in the last 52 weeks. The beta is -0.79, so Revium Rx.'s price volatility has been lower than the market average.
| Beta (5Y) | -0.79 |
| 52-Week Price Change | +175.00% |
| 50-Day Moving Average | 3.34 |
| 200-Day Moving Average | 11.61 |
| Relative Strength Index (RSI) | 47.36 |
| Average Volume (20 Days) | 267 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.11 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -3.26M |
| Pretax Income | -12.89M |
| Net Income | -13.25M |
| EBITDA | -3.25M |
| EBIT | -3.26M |
| Earnings Per Share (EPS) | -0.22 |
Balance Sheet
The company has 1.51 million in cash and 129,000 in debt, with a net cash position of 1.38 million or 0.02 per share.
| Cash & Cash Equivalents | 1.51M |
| Total Debt | 129,000 |
| Net Cash | 1.38M |
| Net Cash Per Share | 0.02 |
| Equity (Book Value) | 5.52M |
| Book Value Per Share | 0.09 |
| Working Capital | 885,000 |
Cash Flow
In the last 12 months, operating cash flow was -2.58 million and capital expenditures -3,000, giving a free cash flow of -2.59 million.
| Operating Cash Flow | -2.58M |
| Capital Expenditures | -3,000 |
| Depreciation & Amortization | 7,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -2.59M |
| FCF Per Share | -0.04 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Revium Rx. does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.59% |
| Shareholder Yield | -8.59% |
| Earnings Yield | -15.26% |
| FCF Yield | -2.98% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 9, 2020. It was a reverse split with a ratio of 0.002.
| Last Split Date | Dec 9, 2020 |
| Split Type | Reverse |
| Split Ratio | 0.002 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |